Department of Internal Medicine, National Taiwan University Hospital Bei-Hu Branch, Taipei, Taiwan.
Department of Chemistry, National Taiwan University, Taipei, 10617, Taiwan.
Rapid Commun Mass Spectrom. 2020 Apr;34 Suppl 1:e8537. doi: 10.1002/rcm.8537. Epub 2020 Feb 20.
The human gut microbiota is a functioning endocrine organ and stands at the intersection between dietary components and health or disease. There are very many microbial metabolites with numerous structures and functions arising from the gut microbial fermentation of foods and become signals for biological communication in the human body. These small molecules can be absorbed and delivered to distant organs through the circulatory system to build the gut-systemic axis. The gut microbial metabolomes are thus believed to play important roles in regulating cardiometabolic health and provide opportunities in mechanistic research and new drug discovery. Measurement of these novel microbial metabolites in clinical samples may serve as a tool for investigating disease biomarkers. In the past decade, the development of untargeted and targeted metabolomics approaches using NMR, LC/MS, and GC/MS has contributed to the exploration of gut microbial metabolomes in cardiometabolic health and disease. Some important targets are currently being translated into clinical applications. In this review article, we introduce an oral carnitine challenge test developed as an example to demonstrate the potential applications in personalized nutrition based on the function of gut microbiota. It is a method taking the gut microbiota as a bioreactor and provides fermentable materials as inputs and measures the outputs of targeted microbial byproducts in the blood or urine. This challenge test may be extended to measure metabolites from microbial fermentation related to other endocrinological or inflammatory diseases. We review current gut metabolome research approaches and propose a gut microbial functional measurement using a challenge test. We suggest that the maturation in measuring gut microbial metabolites may provide an important piece to complete the puzzle of precision medicine.
人类肠道微生物群是一个具有功能的内分泌器官,处于饮食成分与健康或疾病之间的交汇点。肠道微生物对食物的发酵会产生大量具有不同结构和功能的微生物代谢产物,成为人体生物交流的信号。这些小分子可以通过循环系统被吸收并输送到远处的器官,从而构建肠道-全身轴。因此,肠道微生物代谢组被认为在调节心脏代谢健康方面发挥着重要作用,并为机制研究和新药发现提供了机会。测量这些新型微生物代谢产物在临床样本中的含量可能成为研究疾病生物标志物的一种手段。在过去的十年中,使用 NMR、LC/MS 和 GC/MS 的非靶向和靶向代谢组学方法的发展促进了对心脏代谢健康和疾病中肠道微生物代谢组的探索。一些重要的靶点目前正在转化为临床应用。在这篇综述文章中,我们介绍了一种口服肉碱挑战试验,该试验被开发为一个示例,以展示基于肠道微生物群功能的个性化营养中的潜在应用。它是一种以肠道微生物群为生物反应器的方法,提供可发酵的物质作为输入,并测量血液或尿液中靶向微生物副产物的输出。这种挑战试验可以扩展到测量与其他内分泌或炎症性疾病相关的微生物发酵的代谢产物。我们综述了当前的肠道代谢组学研究方法,并提出了一种使用挑战试验来测量肠道微生物功能的方法。我们认为,肠道微生物代谢产物测量方法的成熟可能为精准医学拼图提供重要的一块。